Kyoto University researchers have regenerated neural stem cells in an adult mouse and improved its cognitive function through its method, dubbed "iPaD."
The test results were equivalent to turning a 60-year-old-human's neural stem cells into those of a teenager.
However, there are challenges in applying the procedure to humans because the mouse’s genetic engineering involved using a virus to inject the genes into the brain.
The research team’s leader, visiting professor Ryoichiro Kageyama, said they would continue to see if the procedure can be applied to humans.
The team will now test its iPaD method on marmosets to determine if its applicability to primates.
The ability to multiply embryonic neural stem cells to increase the number of nerve cells weakens with age. That, in turn, results in reduced cognitive function.
The iPaD method maximizes the activation of the neural stem cells by combining the infant mice’s most active genes with a restraining function of the adult mice’s most active genes.
The engineered neural stem cells in an adult mouse became more active with the neural stem cells continuing to multiply for about three months.
|Consequently, the adult mouse improved its cognitive function with the increase in neural stem cell multiplication.


NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
Tabletop particle accelerator could transform medicine and materials science
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Gold Prices Rebound in Asia Amid Iran War Ceasefire Hopes
Japan's Business Confidence Rises Despite Iran War Uncertainty, BOJ Rate Hike Expected
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Goldman Sachs Sees Value in European Real Estate Stocks Despite Sharp Selloff
U.S. Trade Rep Dismisses WTO's Future Role After Failed Cameroon Summit
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Dollar Surges to Monthly High as Middle East Conflict Rattles Global Markets
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



